Cited 6 times in
Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김효송 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 윤상현 | - |
dc.contributor.author | 이혜정 | - |
dc.date.accessioned | 2014-12-18T09:21:25Z | - |
dc.date.available | 2014-12-18T09:21:25Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88019 | - |
dc.description.abstract | PURPOSE: Few studies have investigated the effects of everolimus therapy in Asian populations. This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). METHODS: We retrospectively reviewed records of Korean patients with mRCC (n = 22) who received everolimus between January 2009 and July 2010 and evaluated them for efficacy and safety. RESULTS: One patient achieved a partial response, and 16 patients had stable disease, corresponding to an overall response rate of 4.5 % and a disease control rate of 77.3 %. Median progression-free survival was 5.4 months (95 % CI 0.9-9.8). Median overall survival was not reached. Univariate analysis showed that Memorial Sloan-Kettering Cancer Center risk (P = .004), thrombocytopenia (P = .018), hyperglycemia (P = .007) and hypertriglyceridemia (P = .041) were associated with disease progression. The most common adverse events (AEs) were hypertriglyceridemia and anemia, similar to Western patients. Creatinine and aspartate aminotransferase levels were higher than those reported for Western patients. The most common grade ≥3 AEs in this study were hypertriglyceridemia and anemia, compared with lymphopenia (14 %) in Western patients. CONCLUSIONS: Safety of everolimus in Korean mRCC patients differed from that reported in Western patients. Therefore, liver function enzymes, hemoglobin levels, lipid profile and chest CT scans should be monitored more closely in Asian mRCC patients receiving everolimus. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Renal Cell/pathology | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Monitoring/methods | - |
dc.subject.MESH | Everolimus | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Kidney Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Sirolimus/adverse effects | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Sirolimus/therapeutic use | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Ki Hyang Kim | - |
dc.contributor.googleauthor | Sang Hyun Yoon | - |
dc.contributor.googleauthor | Hae-Jung Lee | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Joong Bae Ahn | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.identifier.doi | 10.1007/s00280-013-2266-y | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A02561 | - |
dc.contributor.localId | A03320 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 23978988 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-013-2266-y | - |
dc.subject.keyword | Everolimus | - |
dc.subject.keyword | Metastatic renal cell carcinoma | - |
dc.subject.keyword | Kidney cancer | - |
dc.subject.keyword | mTOR inhibitor | - |
dc.subject.keyword | Pneumonitis | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.alternativeName | Yoon, Sang Hyun | - |
dc.contributor.alternativeName | Lee, Hye Jeong | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Yoon, Sang Hyun | - |
dc.contributor.affiliatedAuthor | Lee, Hye Jeong | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 72 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 853 | - |
dc.citation.endPage | 860 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.72(4) : 853-860, 2013 | - |
dc.identifier.rimsid | 32707 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.